We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bionomics (BNOX) Meets Goals in PTSD Study, Stock Rallies 244%
Read MoreHide Full Article
Bionomics Limited (BNOX - Free Report) , a clinical-stage Australian biotechnology company, announced positive top-line results from its mid-stage study of BNC210 for the treatment of Post-Traumatic Stress Disorder (PTSD).
BNC210 is Bionomics’ negative allosteric modulator of the α7 nicotinic acetylcholine receptor (nAChR), which is currently being evaluated in separate mid-stage studies for the treatment of Social Anxiety Disorder (SAD) and PTSD.
The phase IIb ATTUNE study met its primary endpoint of a change in the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total symptom severity scorefrom baseline to week 12. Furthermore, the company also reported that a statistically significant change in CAPS-5 score was also observed at week four and week eight.
The mid-stage study also met two of the secondary endpoints of the study with statistical significance, observing improvement in both clinician-administered and patient self-reporting. At week 12, treatment with BNC210 led to significant improvements in depressive symptoms and sleep as measured by the Montgomery-Åsberg Depression Rating Scale and Insomnia Severity Index, respectively.
The stock of the company skyrocketed about 243.8% on Thursday, in response to the encouraging news. Year to date, shares of BNOX have lost 27.6% compared with the industry’s 16.1% fall.
Image Source: Zacks Investment Research
Although not achieved, BNC210 showed positive responses across other secondary endpoints of the ATTUNE study, including the clinician and patient global impression — symptom severity and the Sheehan Disability Scale.
The ATTUNE study enrolled 212 patients in the United States and U.K., who were equally divided into two cohorts, receiving either twice daily 900 mg BNC210 as a monotherapy or placebo for 12 weeks.
The twice-daily BNC210 900 mg had a favorable safety profile and was overall well tolerated. Reported adverse events were mostly mild-to-moderate in severity.
Bionomics is gearing up to hold discussions with the FDA regarding the positive results from the phase IIb ATTUNE study to reach alignment with the regulatory body on the registrational path of BNC210 in PTSD.
Earlier this year, the company announced the full results from its phase II PREVAIL study to evaluate the efficacy and safety of two BNC210 doses (225 mg and 675 mg) for the acute treatment of SAD. Per the study results, treatment with both doses of BNC210 resulted in reductions in anxiety across multiple phases of the public speaking challenge. The candidate also demonstrated a favorable safety and tolerability profile.
Bionomics has reportedly completed its phase III-enabling End-of-phase II meeting with the FDA to advance BNC210 into registrational studies in the SAD indication.
The company also has an ongoing collaboration with Merck (MRK - Free Report) . Notably, MRK is developing a new candidate, MK-4334, which is derived from Bionomics’ original α7 nAChR positive allosteric modulator (PAM) candidate, BNC375.
Bionomics and Merck entered into an exclusive collaboration and license agreement in 2014 to develop investigational candidates utilizing BNOX’s α7 nAChR PAM mechanism of action. Per the agreement, MRK is liable to fund all research and clinical development and worldwide commercialization of any resulting products.
BNOX, so far, has received $20 million from Merck as an upfront payment for the agreement and $10 million upon achieving a phase I milestone. Bionomics is further eligible to receive up to $465 million from Merck for certain development and commercial milestones plus royalties on net sales of licensed drugs.
Bionomics Limited Unsponsored ADR Price and Consensus
A few better-ranked stocks in the same industry are Dynavax Technologies (DVAX - Free Report) and Corcept Therapeutics (CORT - Free Report) , each carrying a Zacks Rank #2 (Buy) at present.
In the past 30 days, the Zacks Consensus Estimate for Dynavax’s 2023 loss per share has narrowed from 24 cents to 23 cents. The estimate for Dynavax’s 2024 earnings per share is currently pegged at 3 cents. Year to date, shares of DVAX have risen by 38.7%.
DVAX’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 25.78%.
In the past 30 days, the Zacks Consensus Estimate for Corcept’s 2023 earnings per share has remained constant at 78 cents. The estimate for Corcept’s 2024 earnings per share has also remained constant at 83 cents. Year to date, shares of CORT have climbed 62.4%.
CORT’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 6.99%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Shutterstock
Bionomics (BNOX) Meets Goals in PTSD Study, Stock Rallies 244%
Bionomics Limited (BNOX - Free Report) , a clinical-stage Australian biotechnology company, announced positive top-line results from its mid-stage study of BNC210 for the treatment of Post-Traumatic Stress Disorder (PTSD).
BNC210 is Bionomics’ negative allosteric modulator of the α7 nicotinic acetylcholine receptor (nAChR), which is currently being evaluated in separate mid-stage studies for the treatment of Social Anxiety Disorder (SAD) and PTSD.
The phase IIb ATTUNE study met its primary endpoint of a change in the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total symptom severity scorefrom baseline to week 12. Furthermore, the company also reported that a statistically significant change in CAPS-5 score was also observed at week four and week eight.
The mid-stage study also met two of the secondary endpoints of the study with statistical significance, observing improvement in both clinician-administered and patient self-reporting. At week 12, treatment with BNC210 led to significant improvements in depressive symptoms and sleep as measured by the Montgomery-Åsberg Depression Rating Scale and Insomnia Severity Index, respectively.
The stock of the company skyrocketed about 243.8% on Thursday, in response to the encouraging news. Year to date, shares of BNOX have lost 27.6% compared with the industry’s 16.1% fall.
Image Source: Zacks Investment Research
Although not achieved, BNC210 showed positive responses across other secondary endpoints of the ATTUNE study, including the clinician and patient global impression — symptom severity and the Sheehan Disability Scale.
The ATTUNE study enrolled 212 patients in the United States and U.K., who were equally divided into two cohorts, receiving either twice daily 900 mg BNC210 as a monotherapy or placebo for 12 weeks.
The twice-daily BNC210 900 mg had a favorable safety profile and was overall well tolerated. Reported adverse events were mostly mild-to-moderate in severity.
Bionomics is gearing up to hold discussions with the FDA regarding the positive results from the phase IIb ATTUNE study to reach alignment with the regulatory body on the registrational path of BNC210 in PTSD.
Earlier this year, the company announced the full results from its phase II PREVAIL study to evaluate the efficacy and safety of two BNC210 doses (225 mg and 675 mg) for the acute treatment of SAD. Per the study results, treatment with both doses of BNC210 resulted in reductions in anxiety across multiple phases of the public speaking challenge. The candidate also demonstrated a favorable safety and tolerability profile.
Bionomics has reportedly completed its phase III-enabling End-of-phase II meeting with the FDA to advance BNC210 into registrational studies in the SAD indication.
The company also has an ongoing collaboration with Merck (MRK - Free Report) . Notably, MRK is developing a new candidate, MK-4334, which is derived from Bionomics’ original α7 nAChR positive allosteric modulator (PAM) candidate, BNC375.
Bionomics and Merck entered into an exclusive collaboration and license agreement in 2014 to develop investigational candidates utilizing BNOX’s α7 nAChR PAM mechanism of action. Per the agreement, MRK is liable to fund all research and clinical development and worldwide commercialization of any resulting products.
BNOX, so far, has received $20 million from Merck as an upfront payment for the agreement and $10 million upon achieving a phase I milestone. Bionomics is further eligible to receive up to $465 million from Merck for certain development and commercial milestones plus royalties on net sales of licensed drugs.
Bionomics Limited Unsponsored ADR Price and Consensus
Bionomics Limited Unsponsored ADR price-consensus-chart | Bionomics Limited Unsponsored ADR Quote
Zacks Rank and Stocks to Consider
Bionomics currently has a Zacks Rank #3 (Hold).
A few better-ranked stocks in the same industry are Dynavax Technologies (DVAX - Free Report) and Corcept Therapeutics (CORT - Free Report) , each carrying a Zacks Rank #2 (Buy) at present.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 30 days, the Zacks Consensus Estimate for Dynavax’s 2023 loss per share has narrowed from 24 cents to 23 cents. The estimate for Dynavax’s 2024 earnings per share is currently pegged at 3 cents. Year to date, shares of DVAX have risen by 38.7%.
DVAX’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 25.78%.
In the past 30 days, the Zacks Consensus Estimate for Corcept’s 2023 earnings per share has remained constant at 78 cents. The estimate for Corcept’s 2024 earnings per share has also remained constant at 83 cents. Year to date, shares of CORT have climbed 62.4%.
CORT’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 6.99%.